# Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas

> **NCT03660930** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Washington** · enrollment: 19 (actual)

## Conditions studied

- Advanced Soft Tissue Sarcoma
- Locally Advanced Soft Tissue Sarcoma
- Metastatic Soft Tissue Sarcoma

## Interventions

- **DRUG:** Sirolimus Albumin-bound Nanoparticles
- **DRUG:** Pazopanib hydrochloride

## Key facts

- **NCT ID:** NCT03660930
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-04-01
- **Primary completion:** 2022-11-17
- **Final completion:** 2024-07-31
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Study was terminated at completion of the Phase 1 dose escalation due to loss of financial support.
- **Last updated:** 2025-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03660930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03660930, "Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03660930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*